Tag: D3S-002
-
D3 Bio Secures FDA Clearance for Two INDs, Advancing D3S‑003 and Elisrasib+D3S‑002 Trials
Overview: Two FDA IND Clearances Accelerate D3 Bio’s Trial Pathways D3 Bio, a pioneering oncology-focused biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications. These approvals unlock a Phase 1 study for D3S‑003 and a Phase 2 study combining Elisrasib (D3S‑001) with D3S‑002. The milestones…
-
D3 Bio Secures FDA Clearance for Two INDs, Jumpstarting Phase 1 and Phase 2 Trials
FDA Clears Two INDs for D3 Bio, Launching Key Clinical Trials Shanghai-based D3 Bio, a clinical-stage biotechnology company focused on transformative oncology therapies, has announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications. The approvals enable a Phase 1 clinical trial for D3S-003 and a Phase 2…
-
D3 Bio Sees FDA IND Clearance for D3S‑003 and Elisrasib Combination Study
FDA Clearance Accelerates D3 Bio’s Oncology Programs The U.S. Food and Drug Administration (FDA) has granted clearance for two Investigational New Drug (IND) applications from D3 Bio, a global clinical‑stage biotechnology company focused on transforming cancer therapy. The approvals authorize a Phase 1 trial of D3S‑003 and a Phase 2 study examining Elisrasib (D3S‑001) in…